Avalyn Pharma Inc. quarterly report, Q3 FY2026

Avalyn Pharma Inc. — Q3 2026 Form 10-Q

Reporting period: Quarter and nine months ended September 30, 2026; unaudited. Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies for pulmonary fibrosis and other rare respiratory diseases. It has no approved products and has generated no product revenue.

Financial performance and position

Amounts below are in millions of dollars except per-share data.

MetricQ3 2026Q3 2025Nine months 2026Nine months 2025
RevenueNoneNoneNoneNone
Research and development expense$25.5$22.1$73.1$55.3
General and administrative expense$7.6$3.2$19.2$10.5
Total operating expenses / operating loss$33.1$25.3$92.3$65.8
Net loss$29.7$23.6$85.5$61.3
Net loss per share, basic and diluted$0.67$20.34$3.39$69.29
Interest income$3.8$1.8$7.6$4.7

Net loss per share is presented as a loss. Year-over-year per-share comparisons are affected by the May 2026 IPO and preferred-stock conversion, which substantially increased the weighted-average common shares. Profit margins are not meaningful because the company has no revenue.

  • Liquidity at September 30, 2026: Cash and cash equivalents were $145.4 million; marketable securities were $241.2 million; combined cash, cash equivalents and securities were $386.6 million. Total current assets were $333.7 million and current liabilities were $13.0 million.
  • Cash flows, nine months: $82.2 million used in operations and $155.5 million used in investing, largely reflecting purchases of marketable securities. Financing provided $330.8 million, primarily from the IPO. Cash and cash equivalents increased $93.1 million to $145.4 million.
  • Debt: $15.0 million principal drawn under a term loan; carrying value was $14.8 million after debt discount. The facility allows another $15.0 million draw through December 31, 2027. Interest is the greater of prime or 5%; prime was 7.0% at quarter-end. Maturity is June 30, 2030.
  • Capital and shares: The May 2026 IPO generated approximately $316.6 million net proceeds. Preferred stock converted to common stock at the IPO. There were 44,389,507 common shares outstanding at September 30 and 44,521,494 as of November 10, 2026.

Material changes versus the prior comparable period

  • Q3 operating expenses rose $7.8 million and net loss increased $6.1 million year over year. For the first nine months, operating expenses increased $26.5 million and net loss increased $24.2 million.
  • R&D growth reflected AP02 Phase 2 activity and increased personnel and stock-based compensation. AP02 direct R&D costs rose $3.0 million in Q3 and $10.6 million for the nine months. AP01 Q3 costs fell $1.8 million as the trial approached completion and patients rolled off; nine-month AP01 costs increased $1.5 million.
  • G&A increased $4.4 million in Q3 and $8.7 million for the nine months, driven by headcount and stock compensation, public-company professional fees, and expanded office space.
  • Interest income increased with the larger post-IPO investment balance. Stock-based compensation was $7.1 million for the nine months, versus $2.4 million in 2025.
  • The company completed its IPO, converted all preferred stock to common stock, and drew $15.0 million on the term loan in 2026.

Outlook, commentary and risks

  • Clinical outlook: AP01 is in the Phase 2b MIST trial in progressive pulmonary fibrosis; the 398-patient trial overenrolled, with topline data expected in the second half of 2027. AP02 is in the ongoing Phase 2 AURA trial in idiopathic pulmonary fibrosis, designed to enroll 160 patients; topline data are expected in late 2027. AP03, an inhaled fixed-dose combination, has begun a Phase 1 study; results are expected in the second half of 2027.
  • Management expects operating expenses and losses to rise as trials, manufacturing, staffing and public-company costs expand. The company expects to need substantial additional funding and has no committed external capital beyond the term-loan facility.
  • Management states that current cash, cash equivalents and marketable securities are expected to fund operations into 2029, based on current plans and assumptions. The financial-statement note separately concludes resources are sufficient for at least 12 months from issuance. Actual runway may be shorter if assumptions, development plans or costs change.
  • Key risks include clinical and regulatory uncertainty; reliance on AP01 and AP02; potential FDA requirements for AP02 and acceptance of foreign-trial data; combination drug-device development; dependence on third-party manufacturers, CROs and PARI’s nebulizer technology; competition; and the possibility of needing dilutive or restrictive financing.
  • The term loan is secured and includes financial and operating restrictions, including negative covenants and events of default. The company reported compliance at September 30, 2026. No litigation was identified that management considers probable to have a material adverse effect; no regulatory milestones under the PARI agreement were achieved in the nine-month period.
  • Management reported effective disclosure controls and procedures at quarter-end and no material change in internal control over financial reporting during the quarter.

Important facts for investors to verify

  • Trial enrollment, execution and data timing for MIST, AURA and the AP03 Phase 1 study, including the stated 2027 topline/result timelines.
  • Cash burn and the assumptions underlying management’s runway estimate into 2029, especially given rising R&D and G&A expenses and the separate minimum 12-month liquidity conclusion.
  • Terms, availability and covenant implications of the remaining $15.0 million term-loan capacity, and the company’s plans for future financing.
  • Regulatory path for AP02, including FDA expectations for an IND and whether foreign Phase 2 data will support later U.S. development.
  • Manufacturing and device-supply capacity, licensing obligations and potential milestone or royalty payments, including obligations under the PARI license and confidential settlement agreement.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.